Prelude Therapeutics Inc at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 04:00PM GMT
Reni Benjamin - JMP Securities LLC - Managing Director

So welcome, everyone. Welcome, good afternoon to the JMP Healthcare Conference. It's my pleasure to introduce Prelude Therapeutics, clinical-stage company developing targeted small molecules. Here to present for the company is founder and CEO, Kris Vaddi.

Kris, welcome to the conference, and thank you for joining us. I never know exactly who's in the audience and who might be listening to the webcast, whether they know the company. So if you could, in maybe three to five minutes, can you give us an overview of Prelude before we jump into some questions?

Kris Vaddi - Prelude Therapeutics Inc. - CEO

Glad to. And thank you very much for the opportunity to participate in this exciting conference. So as you said, Prelude is a small molecule oncology company. We founded the company in late 2016, really, with the idea of building a strong portfolio of highly differentiated and selective and potent small molecule agents to go after key mechanisms that are driving cancers in patients with highly unmet needs.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot